发布求助
文献互助 智能选刊 最新文献

Current opinion in drug discovery & development最新文献

筛选
英文 中文
The synthesis of therapeutic locked nucleos(t)ides. 治疗性锁定核苷的合成。
Current opinion in drug discovery & development Pub Date : 2009-11-01
Chuanzheng Zhou, Jyoti Chattopadhyaya
{"title":"The synthesis of therapeutic locked nucleos(t)ides.","authors":"Chuanzheng Zhou,&nbsp;Jyoti Chattopadhyaya","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This review highlights progress made during the past 2 to 3 years in the field of therapeutic locked nucleos(t)ides. Synthetic strategies to construct the conformationally locked nucleos(t)ides, their properties and potential therapeutic applications as antiviral compounds, and modified oligonucleotides to modulate antisense and RNAi properties are described.</p>","PeriodicalId":10809,"journal":{"name":"Current opinion in drug discovery & development","volume":"12 6","pages":"876-98"},"PeriodicalIF":0.0,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28492876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Solid-phase synthesis of complex and pharmacologically interesting heterocycles. 固相合成复杂的和有药理意义的杂环化合物。
Current opinion in drug discovery & development Pub Date : 2009-11-01
Thomas E Nielsen, Morten Meldal
{"title":"Solid-phase synthesis of complex and pharmacologically interesting heterocycles.","authors":"Thomas E Nielsen,&nbsp;Morten Meldal","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Efficient routes for the creation of heterocycles continue to be one of the primary goals for solid-phase synthesis. Recent advances in this field rely most notably on transition-metal-catalysis and N-acyliminium chemistry to mediate a range of cyclization processes for the generation of compounds with significant structural complexity and diversity. This review describes some of the most systematic solid-phase approaches that are potentially suited for pharmaceutical applications, that is, the methods described are useful for the synthesis of compound collections, and exhibit tunable stereochemistry, scaffold structure, and appendage modification.</p>","PeriodicalId":10809,"journal":{"name":"Current opinion in drug discovery & development","volume":"12 6","pages":"798-810"},"PeriodicalIF":0.0,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28492323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potassium trifluoroborate salts as convenient, stable reagents for difficult alkyl transfers. 三氟硼酸钾盐是用于困难烷基转移的方便、稳定的试剂。
Current opinion in drug discovery & development Pub Date : 2009-11-01
Gary A Molander, Deidre L Sandrock
{"title":"Potassium trifluoroborate salts as convenient, stable reagents for difficult alkyl transfers.","authors":"Gary A Molander, Deidre L Sandrock","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The past decade has witnessed the emergence of potassium organotrifluoroborates as a new class of nucleophilic boron reagents for Suzuki-Miyaura cross-coupling and Rh-catalyzed addition reactions. Potassium organotrifluoroborates are easily prepared, and most are indefinitely stable to air and moisture. Recent advances have focused on the utility of alkyltrifluoroborates in appending alkyl groups selectively and conveniently onto appropriate molecular substructures. This review describes strategies employing these reagents as nucleophilic substrates.</p>","PeriodicalId":10809,"journal":{"name":"Current opinion in drug discovery & development","volume":"12 6","pages":"811-23"},"PeriodicalIF":0.0,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908178/pdf/nihms218286.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28492324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alternative solvent-free methodologies in the synthesis of pharmaceutical drugs. 药物合成中的替代无溶剂方法。
Current opinion in drug discovery & development Pub Date : 2009-11-01
William C Shearouse, Daniel C Waddell, James Mack
{"title":"Alternative solvent-free methodologies in the synthesis of pharmaceutical drugs.","authors":"William C Shearouse,&nbsp;Daniel C Waddell,&nbsp;James Mack","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Efforts made by chemists to develop more sustainable processes have resulted in a large increase in greener technologies. Because solvents comprise greater than 80% by mass of a pharmaceutical batch process, the incorporation of solvent-free reactions is expected to significantly reduce the quantity of hazardous waste that is generated during these processes. This review highlights a diverse set of solvent-free organic reactions that can be employed in the development of various pharmaceutical drugs.</p>","PeriodicalId":10809,"journal":{"name":"Current opinion in drug discovery & development","volume":"12 6","pages":"772-83"},"PeriodicalIF":0.0,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28492321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zero risk and zero benefit: some thoughts on the control of genotoxic impurities. 零风险与零效益:基因毒性杂质控制的几点思考。
Current opinion in drug discovery & development Pub Date : 2009-11-01
John Grosso
{"title":"Zero risk and zero benefit: some thoughts on the control of genotoxic impurities.","authors":"John Grosso","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10809,"journal":{"name":"Current opinion in drug discovery & development","volume":"12 6","pages":"730-1"},"PeriodicalIF":0.0,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28492413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Examples of catalytic asymmetric amine synthesis using organic catalysts. 用有机催化剂催化不对称胺合成的例子。
Current opinion in drug discovery & development Pub Date : 2009-11-01
Ramon Rios, Armando Córdova
{"title":"Examples of catalytic asymmetric amine synthesis using organic catalysts.","authors":"Ramon Rios,&nbsp;Armando Córdova","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The asymmetric construction of optically active amine compounds is of paramount interest for the chemical industry and academic research. This review describes the use of catalytic asymmetric transformations, such as Mannich-type, Michael, cycloaddition and transfer-hydrogenation reactions using small organic molecules (eg, amino acids, secondary amines, peptides, thioureas and phosphoric acids) as catalysts, for the construction of important compounds for medicinal chemistry that exhibit anticancer, antibiotic or antiviral activity.</p>","PeriodicalId":10809,"journal":{"name":"Current opinion in drug discovery & development","volume":"12 6","pages":"824-47"},"PeriodicalIF":0.0,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28492325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic. 新一代抗组胺药:组胺H4受体拮抗剂正在走向临床。
Current opinion in drug discovery & development Pub Date : 2009-09-01
Harald Engelhardt, Rogier A Smits, Rob Leurs, Eric Haaksma, Iwan J P de Esch
{"title":"A new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic.","authors":"Harald Engelhardt,&nbsp;Rogier A Smits,&nbsp;Rob Leurs,&nbsp;Eric Haaksma,&nbsp;Iwan J P de Esch","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>At the turn of the millennium, the DNA sequence encoding the histamine H4 receptor (H4R) was identified in data from human genome databases. Considering the clinical importance of H1R and H2R ligands, and the clinical trials that are ongoing for H3R ligands, the latest addition to the histamine receptor family was noted with interest by the pharmaceutical industry. Initial studies describing the expression of the H4R, and the activity of this receptor in (patho)physiology, suggested that the H4R played a role in the immune system. The introduction of the reference H4R antagonist JNJ-7777120 (Johnson & Johnson Pharmaceutical Research & Development LLC/Abbott Laboratories), and proof of the efficacy of this agent in models of asthma, allergic rhinitis and pruritus, highlighted the H4R as a novel drug target. The first clinical candidates targeting the H4R have been identified, and new H4R antagonists are expected to enter the clinic in the near future.</p>","PeriodicalId":10809,"journal":{"name":"Current opinion in drug discovery & development","volume":"12 5","pages":"628-43"},"PeriodicalIF":0.0,"publicationDate":"2009-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28460552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The importance of target validation in drug discovery and development. 靶点验证在药物发现和开发中的重要性。
Current opinion in drug discovery & development Pub Date : 2009-09-01
John A Lowe, Phil Jones, David M Wilson
{"title":"The importance of target validation in drug discovery and development.","authors":"John A Lowe,&nbsp;Phil Jones,&nbsp;David M Wilson","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10809,"journal":{"name":"Current opinion in drug discovery & development","volume":"12 5","pages":"581-4"},"PeriodicalIF":0.0,"publicationDate":"2009-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28387235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The molecular machinery of mitochondrial fusion and fission: An opportunity for drug discovery? 线粒体融合和裂变的分子机制:药物发现的机会?
Current opinion in drug discovery & development Pub Date : 2009-09-01
Antonio Zorzano, David Sebastián, Jessica Segalés, Manuel Palacín
{"title":"The molecular machinery of mitochondrial fusion and fission: An opportunity for drug discovery?","authors":"Antonio Zorzano,&nbsp;David Sebastián,&nbsp;Jessica Segalés,&nbsp;Manuel Palacín","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The mitochondria form dynamic organized networks or filaments that are controlled by fusion and fission events. A balance between mitochondrial fusion and fission is crucial for the correct function of these organelles. Thus, a detailed characterization of the proteins involved in mitochondrial fusion and fission, and the study of the mechanisms that regulate these two processes, would contribute to elucidating how this balance is achieved. In this regard, alterations in some of the proteins that participate in mitochondrial dynamics are linked to human pathology. In addition, experimental data support the view that mitochondrial metabolism is regulated via the manipulation of the proteins involved in mitochondrial dynamics, particularly the mitofusin 2 protein. This review evaluates the potential of mitochondrial fusion and fission proteins as targets for drug discovery, with an emphasis on mitofusin 2. The pharmacological modulation of mitochondrial dynamics may be beneficial for the treatment of specific disorders of mitochondrial dynamics and mitochondrial-inherited diseases, as well as in complex diseases with a central mitochondrial dysfunction.</p>","PeriodicalId":10809,"journal":{"name":"Current opinion in drug discovery & development","volume":"12 5","pages":"597-606"},"PeriodicalIF":0.0,"publicationDate":"2009-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28460549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. 蛋白精氨酸脱亚胺酶4 (PAD4):目前的认识和未来的治疗潜力。
Current opinion in drug discovery & development Pub Date : 2009-09-01
Justin E Jones, Corey P Causey, Bryan Knuckley, Jessica L Slack-Noyes, Paul R Thompson
{"title":"Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential.","authors":"Justin E Jones,&nbsp;Corey P Causey,&nbsp;Bryan Knuckley,&nbsp;Jessica L Slack-Noyes,&nbsp;Paul R Thompson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The protein arginine deiminases (PADs), and in particular PAD4, have emerged as potential therapeutic targets for the treatment of rheumatoid arthritis (RA). In this review, evidence linking dysregulated PAD activity to the onset and progression of RA is presented, and the potential role of such aberrant activity in other human diseases, such as multiple sclerosis and cancer, is discussed. The known physiological roles of the PADs, particularly PAD4, and current knowledge regarding PAD structure, catalysis and inhibition are also described.</p>","PeriodicalId":10809,"journal":{"name":"Current opinion in drug discovery & development","volume":"12 5","pages":"616-27"},"PeriodicalIF":0.0,"publicationDate":"2009-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771078/pdf/nihms-511984.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28460551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信